Dextromethadone
Dextromethadone is the -enantiomer of methadone. It acts as an N-methyl-D-aspartate receptor antagonist. The compound also has affinity for opioid receptors. As of October 2019, dextromethadone is under development for the treatment of major depressive disorder.
There is now an asymmetric synthesis available to prepare both dextromethadone and levomethadone.
